IL202645A - A chimeric antibody linked to CD37, its DNA-encoded molecule, a pharmaceutical preparation containing it and its use in the preparation of a drug - Google Patents

A chimeric antibody linked to CD37, its DNA-encoded molecule, a pharmaceutical preparation containing it and its use in the preparation of a drug

Info

Publication number
IL202645A
IL202645A IL202645A IL20264509A IL202645A IL 202645 A IL202645 A IL 202645A IL 202645 A IL202645 A IL 202645A IL 20264509 A IL20264509 A IL 20264509A IL 202645 A IL202645 A IL 202645A
Authority
IL
Israel
Prior art keywords
medicament
manufacture
pharmaceutical composition
dna molecule
molecule encoding
Prior art date
Application number
IL202645A
Other languages
English (en)
Hebrew (he)
Other versions
IL202645A0 (en
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL202645(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL202645A0 publication Critical patent/IL202645A0/en
Publication of IL202645A publication Critical patent/IL202645A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL202645A 2007-08-09 2009-12-10 A chimeric antibody linked to CD37, its DNA-encoded molecule, a pharmaceutical preparation containing it and its use in the preparation of a drug IL202645A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114128 2007-08-09
PCT/EP2008/060464 WO2009019312A2 (en) 2007-08-09 2008-08-08 Anti cd37 antibodies

Publications (2)

Publication Number Publication Date
IL202645A0 IL202645A0 (en) 2011-08-01
IL202645A true IL202645A (en) 2016-03-31

Family

ID=38925567

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202645A IL202645A (en) 2007-08-09 2009-12-10 A chimeric antibody linked to CD37, its DNA-encoded molecule, a pharmaceutical preparation containing it and its use in the preparation of a drug

Country Status (37)

Country Link
US (7) US20100189722A1 (enExample)
EP (3) EP2178915B1 (enExample)
JP (3) JP5325216B2 (enExample)
KR (1) KR101593403B1 (enExample)
CN (4) CN101815725A (enExample)
AR (2) AR071242A1 (enExample)
AU (1) AU2008285590B2 (enExample)
BR (2) BRPI0815369A2 (enExample)
CA (1) CA2693464C (enExample)
CL (3) CL2008002349A1 (enExample)
CO (1) CO6251371A2 (enExample)
CY (1) CY1117101T1 (enExample)
DK (1) DK2178915T3 (enExample)
EA (2) EA201200994A1 (enExample)
EC (2) ECSP109946A (enExample)
ES (1) ES2555202T3 (enExample)
HK (1) HK1220708A1 (enExample)
HR (1) HRP20160009T1 (enExample)
HU (1) HUE026221T2 (enExample)
IL (1) IL202645A (enExample)
MA (1) MA32665B1 (enExample)
ME (1) ME02300B (enExample)
MY (1) MY157555A (enExample)
NZ (2) NZ583713A (enExample)
PE (3) PE20090499A1 (enExample)
PH (1) PH12014501812B1 (enExample)
PL (1) PL2178915T3 (enExample)
PT (1) PT2178915E (enExample)
RS (1) RS54359B1 (enExample)
SG (1) SG190657A1 (enExample)
SI (1) SI2178915T1 (enExample)
TN (1) TN2010000068A1 (enExample)
TW (2) TWI535733B (enExample)
UA (2) UA105445C2 (enExample)
UY (1) UY31275A1 (enExample)
WO (1) WO2009019312A2 (enExample)
ZA (1) ZA200908758B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
JP2010540460A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US9023996B2 (en) * 2009-12-23 2015-05-05 Synimmune Gmbh Anti-FLT3 antibodies
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US20120107317A1 (en) * 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
EP2694105A4 (en) * 2011-04-01 2015-04-29 Immunogen Inc CD37 BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
HK1203372A1 (en) 2011-12-13 2015-10-30 Nordic Nanovector Asa Chimeric therapeutic anti - cd37 antibodie hh1
US20150093397A1 (en) * 2012-03-30 2015-04-02 Immunogen, Inc. Methods for Increasing Efficacy of CD37-Based Therapy
US20130287797A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
JP2015517511A (ja) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
WO2013171289A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with further agents
WO2013177367A2 (en) * 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
WO2014151438A1 (en) * 2013-03-15 2014-09-25 Emergent Product Development Seattle, Llc Multispecific anti-cd37 antibodies and related compositions and methods
WO2014198330A1 (en) * 2013-06-14 2014-12-18 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with chlorambucil
AU2014296219A1 (en) 2013-08-01 2016-02-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
US9291244B2 (en) 2014-01-17 2016-03-22 Ford Global Technologies, Llc Nine speed automatic transmission
EP2966085A1 (en) 2014-07-11 2016-01-13 Boehringer Ingelheim International GmbH Antibody IgG1 with a modified heavy chain constant region
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
JP6979877B2 (ja) 2015-06-08 2021-12-15 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ
SI3124976T1 (sl) * 2015-07-28 2018-12-31 F. Hoffmann-La Roche Ag Izboljšan test bakterijskih endotoksinov za določanje endotoksinov
CA2995243A1 (en) 2015-08-28 2017-03-09 Debiopharm International, S.A. Antibodies and assays for detection of cd37
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
JP2020510608A (ja) 2016-11-02 2020-04-09 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
US11578115B2 (en) 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CA3056115A1 (en) 2017-03-16 2018-09-20 The General Hospital Corporation Chimeric antigen receptors targeting cd37
EP3601354A1 (en) 2017-03-31 2020-02-05 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
KR20240135035A (ko) 2017-06-27 2024-09-10 리제너론 파마슈티칼스 인코포레이티드 인간화 asgr1 유전자좌를 포함하는 비인간 동물
JP2021525735A (ja) 2018-05-30 2021-09-27 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７免疫コンジュゲート投薬レジメン
CA3099928A1 (en) * 2018-06-22 2019-12-26 The General Hospital Corporation Chimeric antigen receptors targeting cd37 and cd19
EP3810194A1 (en) 2018-06-22 2021-04-28 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Ｃｄ３７特異的キメラ抗原レセプター
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
AU2020336440A1 (en) * 2019-08-30 2022-03-24 Qilu Puget Sound Biotherapeutics Corporation Anti-CD20 antibodies, anti-CD37 antibodies, and mixtures thereof
CN118339188A (zh) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
US20250333531A1 (en) 2021-10-06 2025-10-30 Nordic Nanovector Asa Humanized hh1
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
IL312237A (en) 2021-10-18 2024-06-01 Daiichi Sankyo Co Ltd Anti-cd37 antibody-drug conjugate
WO2024118480A1 (en) * 2022-11-28 2024-06-06 Epiphany Biosciences Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses
WO2025083205A1 (en) 2023-10-18 2025-04-24 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
ATE190355T1 (de) * 1988-09-06 2000-03-15 Xoma Corp Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
CA2320403A1 (en) 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
DE19911329A1 (de) 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
AU2003259835A1 (en) 2002-08-15 2004-03-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
EP2281577B1 (en) 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20070148170A1 (en) * 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
JP5362359B2 (ja) 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
JP2010532764A (ja) 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2318048B1 (en) 2008-07-21 2019-05-29 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
KR20110083730A (ko) 2008-11-13 2011-07-20 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Ｃｄ37 면역치료제 병용 요법 및 이의 용도
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
US20130287797A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171289A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with further agents
JP2015517511A (ja) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
WO2014198330A1 (en) 2013-06-14 2014-12-18 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with chlorambucil

Also Published As

Publication number Publication date
EA027499B1 (ru) 2017-08-31
JP2011004758A (ja) 2011-01-13
JP2014039541A (ja) 2014-03-06
RS54359B1 (sr) 2016-04-28
AR107902A2 (es) 2018-06-28
TWI535733B (zh) 2016-06-01
US20140010808A1 (en) 2014-01-09
CO6251371A2 (es) 2011-02-21
US20140004110A1 (en) 2014-01-02
US20160137729A1 (en) 2016-05-19
US20210230271A1 (en) 2021-07-29
EP2562187A1 (en) 2013-02-27
WO2009019312A2 (en) 2009-02-12
ME02300B (me) 2016-06-20
PH12014501812A1 (en) 2016-10-24
CL2012002329A1 (es) 2012-12-21
MY157555A (en) 2016-06-30
ES2555202T3 (es) 2015-12-29
HK1220708A1 (zh) 2017-05-12
EP2562187B1 (en) 2019-03-27
CL2011001592A1 (es) 2012-02-17
AR071242A1 (es) 2010-06-09
US20180186876A1 (en) 2018-07-05
BRPI0815369A2 (pt) 2013-03-12
HUE026221T2 (en) 2016-05-30
NZ583713A (en) 2012-07-27
SI2178915T1 (sl) 2016-01-29
TN2010000068A1 (en) 2011-09-26
JP5238000B2 (ja) 2013-07-17
US9078879B2 (en) 2015-07-14
CA2693464C (en) 2017-10-24
EA201000274A1 (ru) 2010-10-29
EP2241577A1 (en) 2010-10-20
UA105445C2 (en) 2014-05-12
KR101593403B1 (ko) 2016-02-12
HRP20160009T1 (hr) 2016-02-12
UY31275A1 (es) 2009-03-31
CL2008002349A1 (es) 2009-10-23
EP2178915A2 (en) 2010-04-28
AU2008285590A1 (en) 2009-02-12
SG190657A1 (en) 2013-06-28
US20100189722A1 (en) 2010-07-29
JP2010535483A (ja) 2010-11-25
CN102276724A (zh) 2011-12-14
AU2008285590B2 (en) 2014-08-14
PE20140196A1 (es) 2014-03-19
WO2009019312A3 (en) 2009-04-30
ECSP109946A (es) 2010-04-30
EA201200994A1 (ru) 2012-12-28
CA2693464A1 (en) 2009-02-12
CY1117101T1 (el) 2017-04-05
TW200916478A (en) 2009-04-16
JP5325216B2 (ja) 2013-10-23
ECSP11009946A (es) 2011-09-30
CN101815725A (zh) 2010-08-25
PH12014501812B1 (en) 2016-10-24
DK2178915T3 (en) 2015-12-14
EP2178915B1 (en) 2015-10-14
PE20090499A1 (es) 2009-05-18
KR20100054791A (ko) 2010-05-25
US20110165153A1 (en) 2011-07-07
UA103005C2 (en) 2013-09-10
PT2178915E (pt) 2016-02-04
US9932399B2 (en) 2018-04-03
PE20120259A1 (es) 2012-04-04
NZ600022A (en) 2013-11-29
BRPI0823331A2 (pt) 2013-07-30
CN105273086A (zh) 2016-01-27
MA32665B1 (fr) 2011-10-02
TW201512220A (zh) 2015-04-01
PL2178915T3 (pl) 2016-03-31
IL202645A0 (en) 2011-08-01
ZA200908758B (en) 2010-08-25
CN103396490A (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
IL202645A (en) A chimeric antibody linked to CD37, its DNA-encoded molecule, a pharmaceutical preparation containing it and its use in the preparation of a drug
IL210485A (en) An isolated antibody or its functional protein, a process for making it, a pharmaceutical preparation containing it, and an isolated amino acid encoding an antibody or a functional protein
IL202443B (en) Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid
IL219268A (en) Anti-b79cd antibody, immunosuppressant and pharmacological agent that includes and uses it
IL188113A (en) Nucleic acid structures encoded with intersectional responses of psma288–297 and prame425–433, or analogs having their intersecting reaction and their use in the preparation of cancer drugs for nucleic acid structures encoded for psma288–297 and prame425–433 cross-reactors Their intersecting response and their use in the preparation of cancer treatment drugs
ZA201000419B (en) Catalyst composition, its preparation and use
IL220412A0 (en) Antibodies which bind to gm-csf, polynucleotides encoding the same, pharmaceutical compositions containing the same and uses thereof
IL234166B (en) Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine
IL213039A (en) Human anti-angiopoietin-2 antibodies, pharmacological compounds containing these antibodies, their nucleic acids encoded, and expression vectors
IL211842A (en) Antibodies or fragments of their human tgfbrii, pharmacological preparations containing them and their use in the preparation of a drug for inhibiting anogenesis
ZA200902409B (en) Lingo binding molecules and pharmaceutical use thereof
IL198592A (en) Proteins linked to 4ig – b7h3, nucleic acids encode it, and methods for creating and using it
IL206554A (en) Targeted transgenic antibody, which identifies 138cd that may be included in a medical device, and its use
ZA200907450B (en) Stabilised pharmaceutical composition containing pregabaline
HUS1800034I1 (hu) Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
EP2199402A4 (en) CYCLOASTRAGENOL MONOGLYCOSIDE, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF
IL186258A0 (en) Chimeric proteins, their preparation and pharmaceutical compositions containing them
IL221723A0 (en) Use of nogo - a binding molecules in the preparation of medicaments
PL2266619T3 (pl) Kompozycja farmaceutyczna na bazie środków chroniących wątrobę i środków prebiotycznych, ich wytwarzanie i zastosowanie
IL193384A0 (en) Substituted prolinamides, their preparation and their use as pharmaceuticals
IL240134A (en) Polypeptides that Increase Testosterone Production, Nucleic Acid Molecules, and Pharmaceutical Preparations Containing Them
ZA201008953B (en) Preparation of molecular sieve containing catalyst and its use in the production of alkylaromatic hydrocarbons
PL2126207T3 (pl) Produkt na bazie mąki, jego wytwarzanie i zastosowanie
IL193117A0 (en) Polypeptide antagonists to cc-chemokine, their preparation and use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed